Transcriptional Dysregulation In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Transcriptional dysregulation is a central pathological feature of neurodegenerative diseases, including alzheimers, parkinsons, als, huntington-pathway, and ftd. The precise regulation of gene expression [1] is essential for neuronal survival, synaptic plasticity, and brain homeostasis, and its disruption contributes directly to neuronal dysfunction and death. Transcriptional dysregulation encompasses aberrant activity of transcription factors, [epigenetic [2] modifications], chromatin [3] remodeling defects, RNA processing errors, and epitranscriptomic alterations that collectively derail the gene expression programs required to maintain neuronal identity and function (Berson et al., 2018))) (Berson et al., 2018). [2:1]
Emerging evidence from single-cell RNA sequencing, ATAC-seq, and epigenomic profiling has revealed that transcriptional changes in neurodegeneration are cell-type-specific, with distinct signatures in excitatory neurons, inhibitory neurons, astrocytes, microglia (Zuccato et al., 2003). [1:1]
The RE1-silencing transcription factor (REST), also known as neuron-restrictive silencer factor (NRSF), plays a critical neuroprotective role in aging and neurodegeneration. In healthy aging brains, REST is upregulated in neurons and represses genes that promote cell death, oxidative stress, and amyloid-beta (amyloid-beta toxicity. In alzheimers, REST is depleted from cortical neurons, leading to de-repression of pro-apoptotic and neurotoxic genes (Lu et al., 2014). REST loss correlates with cognitive decline and is mediated by aberrant nuclear-cytoplasmic transport and proteasomal degradation driven by tau] pathology] (Lu et al., 2014). [4:1]
In huntington-pathway, mutant huntingtin protein] sequesters REST in the cytoplasm, preventing its nuclear translocation and leading to inappropriate activation of neuronal genes in non-neuronal tissues and dysregulation of neurotrophic signaling including BDNF expression (Zuccato et al., 2003) (Li et al., 2025). [3:1]
CREB is a master regulator of neuronal survival, synaptic plasticity, and [long-term potentiation (long-term-potentiation. CREB-mediated transcription is required for memory formation and neuronal resilience. In alzheimers, CREB signaling is impaired through multiple mechanisms: amyloid-beta oligomers disrupt cAMP/PKA signaling upstream of CREB, tau] hyperphosphorylation] interferes with CREB nuclear localization, and reduced CBP/p300 histone acetyltransferase activity diminishes CREB-dependent gene activation (Vitolo et al., 2002) (Vitolo et al., 2002). [5]
CREB dysfunction is also implicated in parkinsons, where loss of dopaminergic signaling in the striatum reduces CREB phosphorylation and transcriptional output, contributing to synaptic-dysfunction and motor circuit degeneration (Bhatt et al., 2019) (Cui et al., 2006). [6]
tfeb is the master regulator of autophagy and lysosomal biogenesis, coordinating the expression of genes involved in cellular waste clearance. In neurodegenerative diseases, mtor-neurodegeneration hyperactivation sequesters tfeb in the cytoplasm, reducing autophagic flux and promoting accumulation of protein aggregates. Overexpression of tfeb rescues neurodegeneration in animal models of Alzheimer's, Parkinson's, and huntington-pathway, establishing tfeb as a promising therapeutic target (Sardiello et al., 2009; Settembre et al., 2011). [7]
nf-kb is a key transcription factor in neuroinflammation and innate immunity. Chronic activation of nf-kb in [microglia drives the sustained production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) that exacerbate neurodegeneration. nf-kb activation is triggered by amyloid-beta, alpha-synuclein, and damage-associated molecular patterns (DAMPs) through tlr4 and nlrp3-inflammasome inflammasome] pathways (Kaltschmidt & Kaltschmidt, 2022). [8]
Yin Yang 1 (YY1) is a dual-function transcription factor that can both activate and repress transcription depending on cellular context. Dysregulation of YY1 has been implicated in multiple neurodegenerative diseases. In Alzheimer's Disease, YY1 levels are altered in affected brain regions, contributing to disrupted expression of genes involved in long-term-potentiation, mitochondrial function, and neuronal survival (Bhalla et al., 2019). [9]
dna-methylation patterns are profoundly altered in neurodegenerative diseases. Global hypomethylation is observed in Alzheimer's Disease brains, particularly at CpG islands associated with genes involved in amyloid processing, tau] phosphorylation], and synaptic function. Specific genes show both hyper- and hypomethylation: the app promoter is hypomethylated (increasing app expression), while neuroprotective genes such as BDNF and SORLA/SORL1 show increased methylation and reduced expression (De Jager et al., 2014). [10]
5-hydroxymethylcytosine (5hmC), an oxidized form of 5-methylcytosine generated by TET enzymes, is enriched in the brain and plays crucial roles in neuronal gene regulation. Reduced 5hmC levels at enhancers and gene bodies are observed in Alzheimer's and Parkinson's Disease, disrupting the expression of synaptic and mitochondrial genes (Zhao et al., 2017). [11]
histone-modifications are extensively dysregulated in neurodegeneration: [12]
Histone acetylation: Reduced histone H3 and H4 acetylation is observed at promoters of memory-related genes in Alzheimer's Disease. hdac-enzymes enzymes], particularly HDAC2 and HDAC6, are elevated in AD brains, silencing synaptic plasticity genes. hdac-enzymes inhibitors rescue memory deficits in AD mouse models and are being explored as therapeutics (Gräff et al., 2012).
CBP/p300 histone acetyltransferases: These epigenetic writers are recruited to chromatin by CREB and other transcription factors to promote gene activation. In AD neurons, CBP/p300 activity is both disrupted and compensatorily activated, leading to complex acetylation changes. Loss of CBP function contributes to impaired synaptic plasticity and memory formation (Active Motif, 2024.
H3K27me3 and H3K4me3: These repressive and activating histone marks, respectively, are redistributed in familial Alzheimer's Disease. PRC2-mediated H3K27me3 deposition at neuronal identity genes leads to transcriptional repression and dedifferentiation of neurons, with REST, PRC2, MYT1L, and SOX11 target genes being silenced through changes in chromatin accessibility (Caldwell et al., 2020).
Histone phosphorylation: γH2AX, a marker of DNA double-strand breaks, is increased in AD neurons, reflecting DNA damage and genomic instability linked to transcriptional stress.
ATP-dependent chromatin remodeling complexes (SWI/SNF, ISWI, CHD, INO80) regulate nucleosome positioning and accessibility of transcription factor binding sites. In neurodegeneration, disrupted chromatin remodeling leads to aberrant gene expression programs: [13]
RNA-binding proteins (RBPs) are central players in RNA metabolism, including splicing, transport, stability, and translation. Their dysfunction is a hallmark of multiple neurodegenerative diseases: [14]
tdp-43: tdp-43 proteinopathy, characterized by nuclear depletion and cytoplasmic aggregation of tdp-43, is the defining pathology of als and FTLD-TDP. Loss of nuclear tdp-43 causes widespread splicing dysregulation, cryptic exon inclusion, and destabilization of thousands of RNA targets, including the stathmin-2 (STMN2) transcript critical for axonal maintenance (Ling et al., 2015; Melamed et al., 2019).
FUS: FUS mutations cause familial ALS and FTD. Nuclear depletion of FUS disrupts transcription, splicing, and DNA damage repair, contributing to motor neuron degeneration (Vance et al., 2009).
hnRNPs: Heterogeneous nuclear ribonucleoproteins (hnRNPs) regulate alternative splicing and are mislocalized in ALS and FTD, contributing to widespread RNA processing defects.
Alternative splicing is particularly complex in the brain, generating transcript diversity essential for neuronal function. Dysregulated splicing contributes to neurodegeneration through: [15]
RNA modifications (the "epitranscriptome") represent an emerging layer of transcriptional regulation disrupted in neurodegeneration: [16]
N6-methyladenosine (m6A): The most abundant internal mRNA modification, m6A regulates RNA stability, splicing, and translation. Altered m6A levels are observed in AD, PD, and ALS brains, affecting stress response pathways, long-term-potentiation, and neuroinflammation. m6A writers (METTL3/14), readers (YTHDF1/2), and erasers (FTO, ALKBH5) are dysregulated in disease states (Li et al., 2025).
Adenosine-to-inosine (A-to-I) RNA editing: Catalyzed by ADAR enzymes, A-to-I editing is highly prevalent in the brain and regulates glutamate receptor function. Reduced editing of the GluA2 subunit of AMPA receptors increases calcium permeability and contributes to excitotoxicity in ALS motor neurons.
5-methylcytidine (m5C) and N1-methyladenosine (m1A): These modifications regulate RNA structure and translation efficiency, and their dysregulation is increasingly linked to neurodegeneration.
MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression. Systematic reviews have identified widespread miRNA dysregulation across neurodegenerative diseases: [17]
Single-nucleus RNA sequencing of AD brains has revealed cell-type-specific transcriptional changes: downregulation of synaptic and mitochondrial genes in excitatory neurons, activation of inflammatory gene programs in microglia, and induction of reactive astrocyte signatures. A key finding is the loss of neuronal identity gene expression, with AD neurons showing dedifferentiation toward a less mature transcriptional state. Individual-specific gene regulatory network analysis has revealed patient-specific dysregulation patterns that may underlie the clinical heterogeneity of AD (MedRxiv, 2025).
In parkinsons, alpha-synuclein in the substantia nigra show specific transcriptional vulnerability characterized by high metabolic demand, complex dendritic arbors, and reliance on calcium-dependent pacemaking, all of which require tight transcriptional control of mitochondrial and calcium-handling genes.
als and ftd feature extensive RNA metabolism defects driven by pathogenic mutations in RNA-binding proteins (tdp-43, FUS, hnRNPA1) and repeat expansion disorders . Nuclear import defects caused by dipeptide repeat proteins disrupt transcription factor localization and drive cell cycle dysregulation in post-mitotic neurons, contributing to neurodegeneration (ResearchGate, 2025).
Mutant huntingtin with expanded polyglutamine repeats directly disrupts transcription by sequestering transcription factors (Sp1, TAFII130, CBP) and altering histone-modifications. The mutant protein also disrupts pgc-1alpha-mediated mitochondrial gene expression, contributing to the bioenergetic deficit characteristic of HD (Cui et al., 2006).
Inhibition of histone deacetylases restores acetylation at memory-related gene promoters and rescues cognitive deficits in AD models. Several hdac-enzymes inhibitors are in clinical development:
Strategies to restore CREB signaling include phosphodiesterase (PDE) inhibitors (e.g., PDE4 inhibitor rolipram), which increase cAMP levels and enhance CREB phosphorylation. These compounds improve memory in preclinical models but face challenges with tolerability.
CRISPR-based epigenome editing tools (dCas9 fused to transcriptional activators or repressors) offer the potential to precisely correct aberrant gene expression patterns in specific neuronal populations. Preclinical studies have demonstrated that targeted activation of neuroprotective genes (e.g., BDNF, [GDNF) can rescue neuronal phenotypes in disease models.
antisense-oligonucleotide-therapy and small interfering RNAs (siRNAs) can correct splicing defects and reduce toxic RNA and protein species. tofersen (targeting [SOD1/proteins/sod1 mRNA in ALS) and nusinersen (correcting SMN2 splicing in [SMA) demonstrate the therapeutic potential of RNA-targeting approaches in neurodegeneration.
Pharmacological activation of tfeb through mtor-neurodegeneration inhibition (rapamycin, Torin1) or direct tfeb activators enhances autophagy-lysosomal clearance of protein aggregates and shows neuroprotective effects across multiple disease models.
Recent advances in single-cell multiomics, spatial transcriptomics, and chromatin profiling are revealing the transcriptional architecture of neurodegeneration with unprecedented resolution. Key research directions include:
The study of Transcriptional Dysregulation In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 18 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 41%
Recent advances in this mechanism are being compiled. Check back for updates on key publications from 2024-2026.
Lu T, Aron L, Bhatt DK, et al. (2014). REST and stress resistance in ageing and Alzheimer's Disease. Nature, 507(7493):448-454. PubMed. 2014. ↩︎ ↩︎
Mathys H, Davila-Velderrain J, Peng Z, et al. (2019). Single-cell transcriptomic analysis of Alzheimer's Disease. Nature, 570(7761):332-337. PubMed. 2019. ↩︎ ↩︎
Sardiello M, Palmieri M, di Ronza A, et al. (2009). A gene network regulating lysosomal biogenesis and function. Science, 325(5939):473-477. PubMed. 2009. ↩︎
De Jager PL, Srivastava G, Lunnon K, et al. (2014). Alzheimer''s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nature Neuroscience, 17(9):1156-1163. PubMed. 2014. ↩︎
Gräff J, Rei D, Guan JS, et al. (2012). An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature, 483(7388):222-226. PubMed. 2012. ↩︎
Caldwell AB, Liu Q, Schroth GP, et al. (2020). Dedifferentiation and neuronal repression define familial Alzheimer's Disease. Science Advances, 6(46):eaba5933. . DOI). 2020. ↩︎
Nativio R, Lan Y, Donahue G, et al. (2020). An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer's Disease. Nature Genetics, 52(10):1024-1035. PubMed. 2020. ↩︎
Melamed Z, López-Erauskin J, Baughn MW, et al. (2019). Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of. tdp-43-dependent neurodegeneration. Nature Neuroscience, 22(2):180-190. PubMed. 2019. ↩︎
Li X, et al. (2025). Epitranscriptomic dysregulation in neurodegenerative diseases and its implications for disease pathology and mechanisms. ScienceDirect. Link. 2025. ↩︎
Bhalla S, et al. (2019). Transcriptional dysregulation in neurodegenerative diseases: who tipped the balance of Yin Yang 1 in the brain? Neural Regeneration Research, 14(7):1148-1150. PMC6425841. 2019. ↩︎
Jurcau A, Ardelean IA. (2019). microRNA dysregulation in neurodegenerative diseases: A systematic review. Progress in Neurobiology, 182:101664. PubMed. 2019. ↩︎
Zhao J, et al. (2017). 5-Hydroxymethylcytosine in Alzheimer''s Disease: from methylation to neurodegeneration. Genomics, Proteomics & Bioinformatics, 15(4):247-253. PubMed. 2017. ↩︎
Cui L, Jeong H, Bhatt DK, et al. (2006). Transcriptional repression of PGC-1alpha by mutant. huntingtin leads to mitochondrial dysfunction. Cell, 127(1):59-69. PubMed. 2006. ↩︎
Liu Y, et al. (2025). RNA dysregulation in neurodegenerative diseases. Molecular Neurodegeneration, 20:5. PubMed. 2025. ↩︎